Home
Live Updates
European Approval Sought for Frontline Amivantamab Plus Lazertinib in EGFR+ NSCLC : comparemela.com
European Approval Sought for Frontline Amivantamab Plus Lazertinib in EGFR+ NSCLC
The EMA is evaluating a Type II extension of indication application for the approval of first-line amivantamab plus lazertinib in EGFR-mutated NSCLC.
Related Keywords
,
Janssen Pharmaceutical Companies Of Johnson ,
European Mediciens Agency ,
European Medicines Agency ,
Johnson ,
Janssen Pharmaceutical Companies ,
Amivantamab ,
Nsclc ,
Lazertinib And Amivantamab ,
Nct04487080 ,
Lazertinib ,
comparemela.com © 2020. All Rights Reserved.